Re-examination Study for General Use to Assess the Safety and Efficacy Profile of Januvia.
Phase of Trial: Phase IV
Latest Information Update: 23 Sep 2014
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 18 Jul 2014 Sulphonylurea and insulin arms added to the treatments, according to ClinicalTrials.gov record.
- 22 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2013 Planned end date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.